Posimir effective for Postsurgical Analgesia approved by FDA

The researchers observed that POSIMIR demonstrated a statistically significant improvement in both primary outcome measures: a 1.3 point, or 20%, reduction in mean pain intensity on a 0-10 point pain scale (p=0.01), and a 67% reduction in I.V. morphine-equivalent rescue opioid use, from a median of 12 mg in the placebo group to 4 mg in the POSIMIR group (p=0.01).

However, Posimir administration reported certain adverse effects which included dizziness, dysgeusia, dysuria, headache, hypoesthesia, paresthesia, tinnitus, and vomiting. Following Posimir administration in soft tissue surgical procedures, the most common adverse reaction included anemia, bradycardia, constipation, C-reactive protein increased, diarrhea, dizziness, dysgeusia, headache, nausea, post-procedural contusion (bruising), procedural pain, pruritus, pyrexia, somnolence, surgical site bleeding, visible bruising, and vomiting.

Hence, the authors discussed that "Posimir was easy to administer into the subacromial space under arthroscopic guidance, where it can directly address the source of postsurgical pain."

A non-opioid product providing up to 3 days of local analgesia would be a significant benefit to patients, they further added.